Shares of Krystal Biotech Inc. (KRYS) surged 5.85% in premarket trading on Wednesday following the company's impressive fourth quarter 2024 financial results and positive updates on its drug pipeline.
The biotech company reported a whopping 406% year-over-year increase in net income to $1.52 per diluted share for Q4, handily beating analyst estimates of $1.16. Revenue soared 116% to $91.1 million, driven by growing sales of VYJUVEK, the first-ever FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa (DEB).
For the full year 2024, VYJUVEK net product revenue skyrocketed 473% to $290.5 million. Krystal ended the year with a robust balance sheet, holding $749.6 million in cash and investments to fund its ambitious drug development plans.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。